Artificial Intelligence and Machine Learning in Drug Discovery (Part I)

In a recent webinar , we surveyed our audience and were surprised to see that a significant majority of attendees thought the application of artificial intelligence and machine learning (AI/ML) methods was the most exciting area for drug discovery, beyond even degraders or molecular glues. Machine learning methods have been increasingly [...]

In a recent webinar , we surveyed our audience and were surprised to see that a significant majority of attendees thought the appl...

The Resurgence of Antibody-Drug Conjugates – FDA Approved ADCs and Linker-Payloads

Antibody-drug conjugates (ADCs) have gone through several waves of enthusiasm since being first tested in animal models in the 1960’s. The first clinical trials with ADCs were conducted in the 1980’s, and an ADC was first approved in 2000 (Mylotarg, see below). Mylotarg, however, was famously withdrawn from the market first, before being [...]

Antibody-drug conjugates (ADCs) have gone through several waves of enthusiasm since being first tested in animal models in the 196...

Kinase Inhibitor Types Predicted with Machine-Learning

You’ve probably lived this story before: you’re working on your favorite kinase, YFK1, and are looking for selective inhibitors over YFK2.  The problem is, they’re virtually identical near the active site, save for a single residue sitting in the back pocket that your amazing structural biologist has identified.  The team [...]

You’ve probably lived this story before: you’re working on your favorite kinase, YFK1, and are looking for selective inhibitors ov...